ADALIMUMAB USAGE CASE IN A PATIENT WITH JUVENILE OLIGOARTHRITIS AND UVEITIS
https://doi.org/10.15690/pf.v10i6.904
Abstract
The article presents a case of a severe progressive course of a juvenile arthritis refractory to the standard antirheumatic therapy. Due to oligosymptomatic disease onset and low adherence of the patient to treatment, the disease was characterized by development of polyarticular joint syndrome with destructive changes (aseptic whirlbone necrosis) and formation of uveitis complicated by a cataract and patient’s incapacitation. Prescription of adalimumab allowed reducing activity of the inflammatory process, considerably improving function of the affected joints, terminating pain syndrome and stiffness and inducing remission of uveitis.
About the Authors
L. A. Balykova
Ogaryov Mordovia State University, Saransk
Russian Federation
PhD, Professor, head of the pediatrics department at the Ogaryov Mordovia State University
Russian Federation
PhD, Professor, head of the pediatrics department at the Ogaryov Mordovia State University
N. V. Ivyanskaya
Republican Child Hospital № 2, Saransk, Mordovia, Russia
Russian Federation
Russian Federation
T. N. Arzamaskina
Republican Child Hospital № 2, Saransk, Mordovia, Russia
Russian Federation
Russian Federation
E. V. Makarkina
Ogarev Mordovian State Medical University, Saransk, Russia
Russian Federation
Russian Federation
Ya. V. Lavskaya
Ogarev Mordovian State Medical University, Saransk, Russia
Russian Federation
Russian Federation
References
1. Alekseeva E. I. Kachestvo zhizni. Meditsina = Life quality. Medicine. 2008; 1: 14–17.
2. Choy E. H., Panayi G. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 2001; 344: 907–916.
3. Schett G. Review: Immune cells and mediators of inflammatory arthritis. Autoimmunity. 2008; 41: 224–229.
4. Barrera P., Th. Boerbooms A. M., Janssen E. M. et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptor, tumor necrosis factor _, and interleukin 6 levels in rheumatoid arthritis. Arthritis Rheum.1993; 36: 1070–1079.
5. Kutukculer N., Caglayan S., Aydogdu F. Study of pro-inflammatory (TNF-_, IL-1_, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin. Rheumatol. 1998; 17: 288–292.
6. Feldmann M., Maini R. Role of cytokines in rheumatoid arthritis: an education in pathophysio-logy and therapeutics. Immunol. Rev. 2008; 223: 7–19.
7. Tak P. P., Taylor P. C., Breedveld F. C. et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor _ monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1996; 39: 1077–1081.
8. Black R. A., Rauch C. T., Kozlosky C. J. et al. A metalloproteinase disintegrin that releases tumor-necrosis factor-_ from cells. Nature. 1997; 385: 729–33.
9. Barksby H. E., Milner J. M., Patterson A. M., Peake N. J. et al. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis. Arthritis Rheum. 2006; 54: 3244–3253.
10. Bradley J.R. TNF-mediated inflammatory disease. J. Pathol. 2008; 214: 149–160.
11. Askermann C., Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin. Ther Tartets. 2007; 11: 1369–1384.
12. Scott D. L., Kingsley G. H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 2006; 355 (7): 704–712.
13. Furst D. E., Keystone E. C., Braun J. et al. Update consensus statement on biological agents for the treatment of rheumatic disease, 2011. Ann Rheum Dis. 2012; 71 (Suppl. II): i2–i45.
14. Kahn P. Juvenile idiopathic arthritis: an update for the clinician. Bulletin of the NYU Hospital for Joint Diseases. 2012; 70 (3): 152–166.
15. Baranov A. A., Alekseeva E. I., Bzarova T. M., Valieva S. I., Denisova R. V., Isaeva K. B., Karagulyan N. A., Litvitskii P. F., Mitenko E. V., Sleptsova T. V., Fetisova A. N., Chistyakova E. G., Taibulatov N. I., Morev S. Yu. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 12 (1): 37–56.
16. Sigidin Ya. A., Lukina G. V. Biologicheskaya terapiya v revmatologii. Izd. 2-e, dop. [Biological Therapy in Rheumatology. 2nd edit., enl.]. Moscow, Practical medicine, 2009. 302 p.
17. Aikawa N. E., DeCarvalho J. F., Silva С A. et al. Immunogenicityof anti-TNFa agents in autoimmune diseases. Clin. Rev. Allerg Immunol. 2010; 38 (2–3): 82–89.
18. Lovell D. J., Ruperto N., Goodman S., Reiff A., Jung L. Pediatric rheumatology collaborative study group, pediatric rheumatology international trials organisation: Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J .Med. 2008, 359: 810–820.
19. Alekseeva E. I., Lisitsyn A. O., Karagulyan N. A. Voprosy sovremennoi pediatrii = Current pediatrics. 2009; 8 (3): 88–94.
20. Imagawa T., Takei S., Umebayashi H., Yamaguchi K., Itoh Y., Kawai T. et al Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin. Rheumatol. 2012 December; 31 (12): 1713–1721.
21. Dixon W. G., Symmons D. P. M., Lunt M. et al. Serious Infection Following Anti-Tumor Necrosis Factor-_ Therapy in Patients With Rheumatoid Arthritis. Arthritis Rheum. 2007; 56: 2896–2904.
22. Lovell D., Ruperto N., Reiff A., Jung Lawrence К., Higgins G., Kone-Paut I., Jones Olcay Y., Mcllraith Melissa J., Andhivarothai N., Kupper H., Giannini Edward H., Peterson Т., Martini A. Long-Term Efficacy and Safety of Adalimumab for up to 6 Years in Patients with Juvenile Idiopathic Arthritis. Abstract presented at: 75th Annual scientific meeting of the American College of Rheumatology (ACR); 11/5/2011. Chicago, IL; USA. 2011. Abstract MIS (7190791).
23. Furst D. E., Schiff M. H., Fleischmann R. M., Strand V., Birbara C. A., Compagnone D. et al. Adalimumab, a fully human anti tumor necrosis factor a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 2003; 30: 2563–2571.
24. Breedveld F. C., Weisman M. H., Kavanaugh A. F. et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate. Arthrit Rheum. 2006; 54: 26–37.
25. Van dePutte L. В., Atkins C., Malaise M., Sany J., Russell A. S., van Riel P. L. et al. Efficacy and safety of Adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 2004; 63: 508–516.
26. Weinblatt M. E., Keystone E. C., Furst D. E. et al. Long term safety, efficacy and remission with adalimumab (Humira) and methotrexate combination therapy in rheumatoid arthritis (RA) 7-year analysis. Abstr. 9th Annual EULAR. 2008 meeting, Paris, AB0343.
27. Simonini G., TaddioA., Cattani M. et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthr Care Res. 2011; 63 (4): 612–618.
28. Alekseeva E.I., Mitenko E.V., Valieva S.I., Bzarova T.M., Denisova R.V., Isaeva K.B., Sleptsova T.V., Chomakhidze A.M. Voprosy sovremennoi pediatrii = Current pediatrics. 2012; 11: 82–90.
29. Galstyan L. A., Zholobova E. S., Rozvadovskaya O. S., Bunin A. V., Starikova A. V. Voprosy sovremennoi pediatrii = Current pediatrics. 2012; 11 (6): 142–146.
30. Malievskii V. A., Nizhevich A. A., Pervushina E. P., Sapronova L. Yu. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 12 (4): 181–184.
Review
For citations:
Balykova L.A., Ivyanskaya N.V., Arzamaskina T.N., Makarkina E.V., Lavskaya Ya.V. ADALIMUMAB USAGE CASE IN A PATIENT WITH JUVENILE OLIGOARTHRITIS AND UVEITIS. Pediatric pharmacology. 2013;10(6):93-97. https://doi.org/10.15690/pf.v10i6.904
Views:
696
Email this article 